Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Corvus Pharma Q3 EPS $(0.12), Inline

Author: Benzinga Newsdesk | November 07, 2023 06:06pm
Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 62.5 percent increase over losses of $(0.32) per share from the same period last year.

Posted In: CRVS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist